We describe the use of this assay to analyze multiple biomarkers of neurodegeneration in the CSF from patients with AD, sporadic FTD, and 2 forms of genetic FTD (patients with mutations in GRN or C9orf72). This evidence concerns the gene C9orf72 and Alzheimer disease.